Despite a pessimistic outlook for the state of the CBD market, the CEO of a leading brand said there’s plenty of opportunity for companies committed to doing things the right way.
A final consent degree has been approved between BASF and a second company and the US Federal Trade Commission to settle a case concerning the use of a fish oil supplement in the treatment of non alcoholic fatty liver disease (NAFLD).
FDA and FTC have warned five companies selling dietary supplements over claims their products could help consumers with infertility and pregnancy problems.
A marketer of CBD products has agreed in a Federal Trade Commission administrative proceeding to cease making unsubstantiated disease treatment claims and pay more than $30,000 in consumer redress.
A proposed class action that attacks a fish oil supplement over its ethyl ester form has been discounted by industry stakeholders who cite the lawsuit’s flawed factual foundation.
A report from a watchdog group found found that just 42% of CBD brands tested all their products for potency. Additionally, the vast majority of products tested were outside the limits of acceptable variance.
A St. Louis-based chiropractor and dietary supplement marketer faces monetary penalties for continuing to market vitamin D and zinc products that purport to prevent COVID-19 infections.
A recent paper claims FDA is in the dark as to how many new ingredients have come onto the market via the GRAS process. Only limited progress has been made in the decade since a Congressional report first raised the issue and directed the Agency to make...
The manufacturer of a multivitamin has withdrawn a number of claims relating to the purported benefits its product has for hyperactive children as part of a National Advertising Division case.
